<p>2025 年 11 月 13 日- 下午 01:10</p>
<p><strong><em>“种子与增强” 方法具有突破潜力，准备改变癌症免疫疗法的格局</em></strong></p>
<p>新加坡--(商业资讯)--ImmunoScape Pte. Ltd.是一家由 A*STAR 孵化的公司，得到安进风险投资和新加坡经济发展局的支持，正在开发下一代基于 T 细胞受体（TCR）的癌症免疫疗法。今天，该公司宣布与 Cue Biopharma Inc.（纳斯达克：CUE）达成独家许可协议，主导开发一种新型疗法，以攻击实体肿瘤癌症。该协议为 ImmunoScape 提供了对 Cue Biopharma 在肿瘤学领域的临床阶段 Immuno-STAT®分子的独家访问权。</p>
<p>通过将 Cue Biopharma 的技术与其精准 T 细胞受体（TCR）疗法相结合，ImmunoScape 正在开创一种新的 “种子与增强” 免疫疗法，解决当前细胞疗法的不足之处，使注入的肿瘤靶向 T 细胞能够在体内有效扩展——以受控的方式在患者体内产生大量高效的肿瘤杀伤 T 细胞。</p>
<p>该策略使用患者自身 T 细胞的最小剂量，经过肿瘤特异性 TCR 工程化（种子），随后定期施用携带 Immuno-STAT®分子的 TCR 匹配和白细胞介素-2（IL-2）（增强）。这种组合免疫疗法首次实现了 IL-2 的真实治疗指数，通过选择性地将其递送到肿瘤反应性 T 细胞，从而消除全身细胞因子毒性，简化生产流程，并可能对恶性细胞进行更深层次、更持久的攻击。</p>
<p><strong>ImmunoScape 的临床项目针对高未满足医疗需求的癌症</strong></p>
<p>ImmunoScape 的首个种子与增强项目针对 WT1 抗原，该抗原在许多顽固的实体肿瘤中表达——包括肺癌、胰腺癌、结直肠癌、卵巢癌、胃癌、黑色素瘤以及头颈癌——以及某些血液恶性肿瘤，这些癌症仍然代表着显著的未满足临床需求。ImmunoScape 在新加坡的实验室在多个实体肿瘤模型中生成了引人注目的临床前数据，这些数据支持 IND 启用研究，预计将在 2027 年开始临床试验。</p>
<p>“我们在新加坡的体内癌症模型展示了这种新方法在多种实体肿瘤中的有效性，” ImmunoScape 的发现副总裁 Dr. Kar Wai Tan 博士说。</p>
<p>公司的模块化种子与增强平台技术有潜力通过提供安全、耐受性良好且有效的癌症疗法来改变细胞疗法，同时简化患者的治疗过程。除了针对实体肿瘤，该平台还可以用于增强现有的经典自体和体内 T 细胞疗法。ImmunoScape 的临床研究将包括与亚洲人群相关的癌症和免疫类型。</p>
<p>“ImmunoScape 正在开创下一波癌症治疗，” ImmunoScape 的首席执行官 Michael Fehlings 博士说。“通过我们的下一代种子与增强策略，我们旨在在多种癌症中提供临床上有意义的患者结果改善。”</p>
<p><strong>ImmunoScape 通过关键任命加强领导层</strong></p>
<p>在转型为全球癌症免疫疗法开发领导者的过程中，ImmunoScape 很高兴地宣布对其领导结构的补充：</p>
<ul>
<li><strong>Usman &#34;Oz&#34; Azam, MD，加入董事会：</strong> Azam 博士是 Cue Biopharma 的总裁兼首席执行官，曾担任诺华细胞和基因治疗业务的全球负责人，带来了波士顿的 Cue Biopharma 的支持和在细胞疗法开发、生产和商业化方面的丰富经验。Azam 博士曾担任 Inspirna, Inc.的首席执行官，该公司是一家专注于新型癌症药物发现和开发的私营临床阶段生物制药公司，并曾担任 Tmunity Therapeutics 的总裁兼首席执行官，参与开发用于实体肿瘤应用的基因工程 CAR-T 细胞疗法。</li>
</ul>
<ul>
<li><strong>Adrian Bot, MD/PhD，加入董事会：</strong> Bot 博士在免疫疗法的发现、开发和商业化方面拥有 27 年的经验，包括 CAR 和 TCR 工程化 T 细胞产品。他是 Capstan Therapeutics 的创始首席科学官，专注于体内 CAR 疗法，并曾担任 Kite Pharma 的首席科学官和全球转化医学与研究负责人，开发开创性的基因工程 T 细胞疗法。</li>
</ul>
<p>“实体肿瘤中的免疫疗法正处于一个关键时刻，需要复杂的精准医学工具来有效地协调持久的临床反应。我相信 ImmunoScape 的新型免疫治疗工具将推动癌症患者在广泛癌症类型中的需求得到更好的满足。他们的创新种子与增强方法在癌症领域具有全球意义，” Bot 博士说。</p>
<ul>
<li><strong>Pamela Munster, MD，加入科学顾问委员会：</strong> Pamela Munster 博士是一位杰出的医学肿瘤学家，担任 UCSF 早期阶段肿瘤临床试验项目的主任，加入并补充了科学顾问委员会现有的专家，带来了对未满足实体肿瘤患者需求的无与伦比的临床见解。Munster 博士是获奖书籍《扭转命运：我与 BRCA 的旅程——从乳腺癌医生到患者再到医生》的作者。</li>
</ul>
<p><strong>一家得到本地和全球合作伙伴支持的新加坡生物科技公司</strong></p>
<p>ImmunoScape 感谢其早期合作伙伴和投资者使这一开创性工作成为可能。该公司还感谢 A*STAR 提供的基础研究支持，以及新加坡企业发展局和新加坡经济发展局（EDB）对支持公司新加坡运营的承诺。该公司感谢其财务投资者，包括 EDB Investments、Amgen Ventures 和 Anzu Partners 对其平台和使命的共同信念。</p>
<p><strong>关于 ImmunoScape</strong></p>
<p>ImmunoScape 是一家总部位于新加坡的顶尖临床阶段生物技术公司，专注于发现和开发下一代肿瘤细胞免疫疗法。ImmunoScape 在新加坡和加利福尼亚开展业务，推动创新，以提供针对实体肿瘤的变革性治疗。欲了解更多信息，请访问 <strong>immunoscape.com</strong>。</p>
<p><strong>关于 Cue Biopharma</strong></p>
<p>Cue Biopharma 是一家临床阶段的生物制药公司，开发一种新型可注射生物制剂，旨在直接在患者体内选择性地激活和调节特定疾病的 T 细胞。该公司的专有平台 Immuno-STAT® <em>(选择性靶向和改变 T 细胞)</em> 和生物制剂旨在利用身体内在免疫系统的治愈潜力，而不产生广泛系统性免疫调节的副作用。</p>
<p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNjg4NTVyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNjg4NTVyMQ"/></p>
<p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251113268855/en/</p>
<p><strong>ImmunoScape 媒体联系人</strong></p>
<p>Kalyn Schieffer</p>
<p>公关负责人</p>
<p>Anzu Partners 为 ImmunoScape 提供服务</p>
<p>kos@anzupartners.com</p>
<p>Cue Biopharma 投资者联系人</p>
<p>Marie Campinell</p>
<p>企业传播高级总监</p>
<p>Cue Biopharma, Inc.</p>
<p>mcampinell@cuebio.com</p>
<p>Cue Biopharma 媒体联系人</p>
<p>Jonathan Pappas</p>
<p>LifeSci Communications</p>
<p>jpappas@lifescicomms.com</p>
<p>来源：ImmunoScape Pte. Ltd.</p>

<p>新加坡生物科技公司 ImmunoScape Pte. Ltd.宣布与 Cue Biopharma 达成独家许可协议，开发针对实体肿瘤的下一代细胞疗法，采用 “种子与增强” 方法。该公司还通过关键任命加强了领导层，包括 Usman Azam 和 Adrian Bot 加入董事会，以及 Pamela Munster 加入科学顾问委员会。这一战略举措旨在转变癌症免疫疗法，并解决实体肿瘤未满足的医疗需求</p>

<p>11/13/2025 - 01:10 PM</p>
<div class="lb-trans"><p>2025 年 11 月 13 日- 下午 01:10</p>
</div><p><strong><em>“Seed-and-Boost” Approach with Breakthrough Potential, Poised to Transform the Cancer Immunotherapy Landscape</em></strong></p>
<div class="lb-trans"><p><strong><em>“种子与增强” 方法具有突破潜力，准备改变癌症免疫疗法的格局</em></strong></p>
</div><p>SINGAPORE--(BUSINESS WIRE)--ImmunoScape Pte. Ltd., an A*STAR spin out backed by Amgen Ventures and EDBi that is developing next-generation TCR-based cancer immunotherapies, today announced an exclusive in-licensing deal with Cue Biopharma Inc. (Nasdaq: CUE) to lead the development of a distinct new class of therapies to attack solid tumor cancers. The deal provides ImmunoScape with exclusive access to Cue Biopharma’s clinical-stage Immuno-STAT® molecules in oncology.</p>
<div class="lb-trans"><p>新加坡--(商业资讯)--ImmunoScape Pte. Ltd.是一家由 A*STAR 孵化的公司，得到安进风险投资和新加坡经济发展局的支持，正在开发下一代基于 T 细胞受体（TCR）的癌症免疫疗法。今天，该公司宣布与 Cue Biopharma Inc.（纳斯达克：CUE）达成独家许可协议，主导开发一种新型疗法，以攻击实体肿瘤癌症。该协议为 ImmunoScape 提供了对 Cue Biopharma 在肿瘤学领域的临床阶段 Immuno-STAT®分子的独家访问权。</p>
</div><p>By combining Cue Biopharma’s technology with its precision T cell receptor (TCR) therapy, ImmunoScape is pioneering a new “Seed-and-Boost” approach to immunotherapy, that addresses the shortcomings of current cell therapies by enabling potent <em>in vivo</em> expansion of infused tumor targeting T-cells—producing large numbers of highly effective tumor killing T cells in a controlled manner in the patient.</p>
<div class="lb-trans"><p>通过将 Cue Biopharma 的技术与其精准 T 细胞受体（TCR）疗法相结合，ImmunoScape 正在开创一种新的 “种子与增强” 免疫疗法，解决当前细胞疗法的不足之处，使注入的肿瘤靶向 T 细胞能够在体内有效扩展——以受控的方式在患者体内产生大量高效的肿瘤杀伤 T 细胞。</p>
</div><p>The strategy uses a minimal dose of the patient’s own T cells, engineered with a tumor-specific TCR (Seed), followed by periodic administration of TCR-matching and interleukin-2 (IL-2) carrying Immuno-STAT® molecules (Boost). This combination immunotherapy enables, for the first time, the establishment of a true therapeutic index for IL-2 by selectively delivering it to tumor-reactive T cells. The potential breakthrough approach offers to eliminate systemic cytokine toxicity, streamline manufacturing, and may deliver a deeper, more durable attack on malignant cells.</p>
<div class="lb-trans"><p>该策略使用患者自身 T 细胞的最小剂量，经过肿瘤特异性 TCR 工程化（种子），随后定期施用携带 Immuno-STAT®分子的 TCR 匹配和白细胞介素-2（IL-2）（增强）。这种组合免疫疗法首次实现了 IL-2 的真实治疗指数，通过选择性地将其递送到肿瘤反应性 T 细胞，从而消除全身细胞因子毒性，简化生产流程，并可能对恶性细胞进行更深层次、更持久的攻击。</p>
</div><p><strong>ImmunoScape’s clinical program targets cancers of high unmet medical need</strong></p>
<div class="lb-trans"><p><strong>ImmunoScape 的临床项目针对高未满足医疗需求的癌症</strong></p>
</div><p>ImmunoScape’s first Seed-and-Boost program targets the WT1 antigen, which is expressed across many recalcitrant solid tumors — including lung, pancreatic, colorectal, ovarian, gastric, melanoma, and head and neck cancers — as well as certain hematologic malignancies that still represent significant unmet clinical needs. ImmunoScape’s Singapore lab has generated compelling preclinical data across multiple solid tumor models, which is supportive of IND-enabling studies that will enable clinical trials to commence by 2027.</p>
<div class="lb-trans"><p>ImmunoScape 的首个种子与增强项目针对 WT1 抗原，该抗原在许多顽固的实体肿瘤中表达——包括肺癌、胰腺癌、结直肠癌、卵巢癌、胃癌、黑色素瘤以及头颈癌——以及某些血液恶性肿瘤，这些癌症仍然代表着显著的未满足临床需求。ImmunoScape 在新加坡的实验室在多个实体肿瘤模型中生成了引人注目的临床前数据，这些数据支持 IND 启用研究，预计将在 2027 年开始临床试验。</p>
</div><p>“Our Singapore-based in vivo cancer models demonstrate the efficacy of this new approach in multiple solid tumors” said Dr. Kar Wai Tan PhD, ImmunoScape’s Vice President of Discovery.</p>
<div class="lb-trans"><p>“我们在新加坡的体内癌症模型展示了这种新方法在多种实体肿瘤中的有效性，” ImmunoScape 的发现副总裁 Dr. Kar Wai Tan 博士说。</p>
</div><p>The Company’s modular Seed-and-Boost platform technology has the potential to transform cell therapy, through the delivery of safe, tolerable and effective therapies against cancer while simplifying the patient journey. In addition to targeting solid tumors, the platform may also be used to enhance existing classic autologous and in vivo T cell therapies. ImmunoScape’s clinical studies will include cancers and immune types that are relevant to Asian populations.</p>
<div class="lb-trans"><p>公司的模块化种子与增强平台技术有潜力通过提供安全、耐受性良好且有效的癌症疗法来改变细胞疗法，同时简化患者的治疗过程。除了针对实体肿瘤，该平台还可以用于增强现有的经典自体和体内 T 细胞疗法。ImmunoScape 的临床研究将包括与亚洲人群相关的癌症和免疫类型。</p>
</div><p>“ImmunoScape is pioneering the next wave of cancer therapeutics,” said Michael Fehlings, PhD, CEO of ImmunoScape. “Through our next-generation Seed-and-Boost strategy, we aim to deliver clinically meaningful improvements in patient outcomes in multiple cancers.”</p>
<div class="lb-trans"><p>“ImmunoScape 正在开创下一波癌症治疗，” ImmunoScape 的首席执行官 Michael Fehlings 博士说。“通过我们的下一代种子与增强策略，我们旨在在多种癌症中提供临床上有意义的患者结果改善。”</p>
</div><p><strong>ImmunoScape Strengthens Leadership with Key Appointments</strong></p>
<div class="lb-trans"><p><strong>ImmunoScape 通过关键任命加强领导层</strong></p>
</div><p>As it transitions to becoming a global leader in cancer immunotherapy development, ImmunoScape is pleased to announce additions to its leadership structure:</p>
<div class="lb-trans"><p>在转型为全球癌症免疫疗法开发领导者的过程中，ImmunoScape 很高兴地宣布对其领导结构的补充：</p>
</div><ul>
<li><strong>Usman &#34;Oz&#34; Azam, MD, Joins the Board of Directors:</strong> Dr. Azam, President and CEO of Cue Biopharma and former global head of Novartis' Cell and Gene Therapy business, brings the support of Boston-based Cue Biopharma and extensive expertise in cell therapy development, manufacturing and commercialization. Dr. Azam served as Chief Executive Officer of Inspirna, Inc., a privately held clinical stage biopharmaceutical company focused on the discovery and development of novel cancer drugs and President and CEO of Tmunity Therapeutics, where he was involved in developing genetically engineered CAR-T cell therapies for solid tumor applications in cancer.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Usman &#34;Oz&#34; Azam, MD，加入董事会：</strong> Azam 博士是 Cue Biopharma 的总裁兼首席执行官，曾担任诺华细胞和基因治疗业务的全球负责人，带来了波士顿的 Cue Biopharma 的支持和在细胞疗法开发、生产和商业化方面的丰富经验。Azam 博士曾担任 Inspirna, Inc.的首席执行官，该公司是一家专注于新型癌症药物发现和开发的私营临床阶段生物制药公司，并曾担任 Tmunity Therapeutics 的总裁兼首席执行官，参与开发用于实体肿瘤应用的基因工程 CAR-T 细胞疗法。</li>
</ul>
</div><ul>
<li><strong>Adrian Bot, MD/PhD, Joins the Board of Directors:</strong> Dr. Bot brings 27 years of experience in discovery, development and commercialization of immunotherapies including CAR and TCR-engineered T cell products. He was the founding CSO for Capstan Therapeutics focused on in vivo CAR therapies and has held leadership positions including CSO and Global Head of Translational Medicine and Research at Kite Pharma developing groundbreaking gene engineered T cell therapies.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Adrian Bot, MD/PhD，加入董事会：</strong> Bot 博士在免疫疗法的发现、开发和商业化方面拥有 27 年的经验，包括 CAR 和 TCR 工程化 T 细胞产品。他是 Capstan Therapeutics 的创始首席科学官，专注于体内 CAR 疗法，并曾担任 Kite Pharma 的首席科学官和全球转化医学与研究负责人，开发开创性的基因工程 T 细胞疗法。</li>
</ul>
</div><p>“Immunotherapy in solid tumors is at a juncture, when sophisticated, precision medicine tools are needed to effectively orchestrate a durable clinical response, I am convinced that the novel immunotherapeutic tools of ImmunoScape will push the boundaries towards better addressing the needs of cancer patients in a broad range of cancer types. Their innovative Seed and Boost approach is of global significance in the cancer field,” said Dr. Bot.</p>
<div class="lb-trans"><p>“实体肿瘤中的免疫疗法正处于一个关键时刻，需要复杂的精准医学工具来有效地协调持久的临床反应。我相信 ImmunoScape 的新型免疫治疗工具将推动癌症患者在广泛癌症类型中的需求得到更好的满足。他们的创新种子与增强方法在癌症领域具有全球意义，” Bot 博士说。</p>
</div><ul>
<li><strong>Pamela Munster, MD, Joins Scientific Advisory Board:</strong> Dr. Pamela Munster, a distinguished medical oncologist and Director of the early-stage oncology clinical trials program at UCSF, joins and complements the existing experts on the Scientific Advisory Board, bringing unparalleled clinical insights into unmet solid tumor patient needs. Dr. Munster is the author of the award-winning book, <em>Twisting Fate: My Journey with BRCA―from Breast Cancer Doctor to Patient and Back</em>.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Pamela Munster, MD，加入科学顾问委员会：</strong> Pamela Munster 博士是一位杰出的医学肿瘤学家，担任 UCSF 早期阶段肿瘤临床试验项目的主任，加入并补充了科学顾问委员会现有的专家，带来了对未满足实体肿瘤患者需求的无与伦比的临床见解。Munster 博士是获奖书籍《扭转命运：我与 BRCA 的旅程——从乳腺癌医生到患者再到医生》的作者。</li>
</ul>
</div><p><strong>A Singapore Biotech Supported by Local and Global Partners</strong></p>
<div class="lb-trans"><p><strong>一家得到本地和全球合作伙伴支持的新加坡生物科技公司</strong></p>
</div><p>ImmunoScape thanks its early partners and investors for making this pioneering work possible. The company is, additionally, grateful to A*STAR for foundational research support, and Enterprise Singapore and the Singapore Economic Development Board (EDB) for their commitment to supporting the company’s Singapore operations. The company thanks its financial investors, including EDB Investments, Amgen Ventures, and Anzu Partners for their shared belief in its platform and mission.</p>
<div class="lb-trans"><p>ImmunoScape 感谢其早期合作伙伴和投资者使这一开创性工作成为可能。该公司还感谢 A*STAR 提供的基础研究支持，以及新加坡企业发展局和新加坡经济发展局（EDB）对支持公司新加坡运营的承诺。该公司感谢其财务投资者，包括 EDB Investments、Amgen Ventures 和 Anzu Partners 对其平台和使命的共同信念。</p>
</div><p><strong>About ImmunoScape</strong></p>
<div class="lb-trans"><p><strong>关于 ImmunoScape</strong></p>
</div><p>ImmunoScape is a premier, clinical-stage Singapore-headquartered biotechnology company focused on the discovery and development of next-generation cell immunotherapies in oncology. With operations in Singapore and California, ImmunoScape drives innovation to deliver transformative treatments for solid tumors. For more information, please visit <strong>immunoscape.com</strong>.</p>
<div class="lb-trans"><p>ImmunoScape 是一家总部位于新加坡的顶尖临床阶段生物技术公司，专注于发现和开发下一代肿瘤细胞免疫疗法。ImmunoScape 在新加坡和加利福尼亚开展业务，推动创新，以提供针对实体肿瘤的变革性治疗。欲了解更多信息，请访问 <strong>immunoscape.com</strong>。</p>
</div><p><strong>About Cue Biopharma</strong></p>
<div class="lb-trans"><p><strong>关于 Cue Biopharma</strong></p>
</div><p>Cue Biopharma is a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT® <em>(Selective Targeting and Alteration of T cells)</em>, and biologics are designed to harness the curative potential of the body’s intrinsic immune system without the adverse effects of broad systemic immune modulation.</p>
<div class="lb-trans"><p>Cue Biopharma 是一家临床阶段的生物制药公司，开发一种新型可注射生物制剂，旨在直接在患者体内选择性地激活和调节特定疾病的 T 细胞。该公司的专有平台 Immuno-STAT® <em>(选择性靶向和改变 T 细胞)</em> 和生物制剂旨在利用身体内在免疫系统的治愈潜力，而不产生广泛系统性免疫调节的副作用。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1hY3FyOCZzdHk9MjAyNTExMTMyNjg4NTVyMQ" alt="" original-src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20251113268855r1&amp;sid=acqr8&amp;distro=nx&amp;lang=en"/></p>
<p>View source version on businesswire.com: https://www.businesswire.com/news/home/20251113268855/en/</p>
<div class="lb-trans"><p>在 businesswire.com 查看源版本：https://www.businesswire.com/news/home/20251113268855/en/</p>
</div><p><strong>ImmunoScape Media Contact</strong></p>
<div class="lb-trans"><p><strong>ImmunoScape 媒体联系人</strong></p>
</div><p>Kalyn Schieffer</p>
<div class="lb-trans"><p>Kalyn Schieffer</p>
</div><p>Principal, Public Relations</p>
<div class="lb-trans"><p>公关负责人</p>
</div><p>Anzu Partners for ImmunoScape</p>
<div class="lb-trans"><p>Anzu Partners 为 ImmunoScape 提供服务</p>
</div><p>kos@anzupartners.com</p>
<div class="lb-trans"><p>kos@anzupartners.com</p>
</div><p>Investor Contact for Cue Biopharma</p>
<div class="lb-trans"><p>Cue Biopharma 投资者联系人</p>
</div><p>Marie Campinell</p>
<div class="lb-trans"><p>Marie Campinell</p>
</div><p>Senior Director, Corporate Communications</p>
<div class="lb-trans"><p>企业传播高级总监</p>
</div><p>Cue Biopharma, Inc.</p>
<div class="lb-trans"><p>Cue Biopharma, Inc.</p>
</div><p>mcampinell@cuebio.com</p>
<div class="lb-trans"><p>mcampinell@cuebio.com</p>
</div><p>Media Contact for Cue Biopharma</p>
<div class="lb-trans"><p>Cue Biopharma 媒体联系人</p>
</div><p>Jonathan Pappas</p>
<div class="lb-trans"><p>Jonathan Pappas</p>
</div><p>LifeSci Communications</p>
<div class="lb-trans"><p>LifeSci Communications</p>
</div><p>jpappas@lifescicomms.com</p>
<div class="lb-trans"><p>jpappas@lifescicomms.com</p>
</div><p>Source: ImmunoScape Pte. Ltd.</p>
<div class="lb-trans"><p>来源：ImmunoScape Pte. Ltd.</p>
</div>

Singapore-based ImmunoScape Pioneers Next-Generation Cell Therapy for Solid Tumors; Announces Key Licensing Deal, New Board and SAB Appointments | CUE Stock News

总部位于新加坡的 ImmunoScape 公司在实体瘤的下一代细胞疗法领域开创了先河；宣布达成重要的许可协议，并任命了新的董事会成员和科学顾问委员会成员 | Cue BioPharma 股票新闻